DXCM

— Fundamental Stock Analysis and Report Card

Healthcare : Medical - Devices

Located in San Diego, CA, US. DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Growth

Revenue, earnings and profitability.

Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.

Revenue History

Earnings History

Margins

Gross Margin TTM
61.84%
EBITDA Margin TTM
30.64%
Net Margin TTM
19.31%
Earnings Per Share TTM
2.42
Statements

Income & Cash Flow analysis.

An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.

DexCom, Inc.
Select Period:
Q1 2026
Total ($)
Q1 2026
Margin (%)
Revenue
1.2b
+155.9m
+15.0%
Gross Income
750.3m
+161.3m
+27.4%
63%
+6.1pp
+10.7%
EBITDA
336.6m
+117.6m
+53.7%
28%
+7.1pp
+33.6%
Operating Income
255.3m
+121.6m
+90.9%
21%
+8.5pp
+66.0%
Net Income
199.5m
+94.1m
+89.3%
17%
+6.6pp
+64.5%
Earnings Per Share
0.52
+0.3
+92.6%
Operating Cash Flow
525.6m
+341.8m
+186.0%
44%
+26.4pp
+148.6%
Free Cash Flow
449.0m
+352.2m
+363.8%
38%
+28.3pp
+303.2%
Research & Development
145.3m
+100.0k
+0.1%
12%
-1.8pp
-13.0%